ATyr Non Current Assets Total from 2010 to 2024
| LIFE Stock | USD 1.60 0.02 1.23% |
Non Current Assets Total | First Reported 2010-03-31 | Previous Quarter 17.4 M | Current Value 19.1 M | Quarterly Volatility 3.2 B |
Check ATyr Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ATyr main balance sheet or income statement drivers, such as Interest Expense of 2 M, Selling General Administrative of 12.3 M or Total Revenue of 335.4 K, as well as many exotic indicators such as Price To Sales Ratio of 225, Dividend Yield of 0.0 or PTB Ratio of 0.79. ATyr financial statements analysis is a perfect complement when working with ATyr Pharma Valuation or Volatility modules.
ATyr | Non Current Assets Total |
Latest ATyr Pharma's Non Current Assets Total Growth Pattern
Below is the plot of the Non Current Assets Total of aTyr Pharma over the last few years. It is the total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets. ATyr Pharma's Non Current Assets Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ATyr Pharma's overall financial position and show how it may be relating to other accounts over time.
| Non Current Assets Total | 10 Years Trend |
|
Non Current Assets Total |
| Timeline |
ATyr Non Current Assets Total Regression Statistics
| Arithmetic Mean | 1,442,055,683 | |
| Geometric Mean | 21,890,072 | |
| Coefficient Of Variation | 206.10 | |
| Mean Deviation | 2,296,090,527 | |
| Median | 4,326,000 | |
| Standard Deviation | 2,972,089,013 | |
| Sample Variance | 8833313.1T | |
| Range | 7.4B | |
| R-Value | (0.70) | |
| Mean Square Error | 4912578.7T | |
| R-Squared | 0.48 | |
| Significance | 0 | |
| Slope | (462,148,944) | |
| Total Sum of Squares | 123666383.5T |
ATyr Non Current Assets Total History
About ATyr Pharma Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include ATyr Pharma income statement, its balance sheet, and the statement of cash flows. ATyr Pharma investors use historical funamental indicators, such as ATyr Pharma's Non Current Assets Total, to determine how well the company is positioned to perform in the future. Although ATyr Pharma investors may use each financial statement separately, they are all related. The changes in ATyr Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on ATyr Pharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on ATyr Pharma Financial Statements. Understanding these patterns can help to make the right decision on long term investment in ATyr Pharma. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Non Current Assets Total | 19.1 M | 18.1 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of ATyr Pharma Correlation against competitors. For information on how to trade ATyr Stock refer to our How to Trade ATyr Stock guide.Note that the aTyr Pharma information on this page should be used as a complementary analysis to other ATyr Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Complementary Tools for ATyr Stock analysis
When running ATyr Pharma's price analysis, check to measure ATyr Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ATyr Pharma is operating at the current time. Most of ATyr Pharma's value examination focuses on studying past and present price action to predict the probability of ATyr Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ATyr Pharma's price. Additionally, you may evaluate how the addition of ATyr Pharma to your portfolios can decrease your overall portfolio volatility.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |
Is ATyr Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ATyr Pharma. If investors know ATyr will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ATyr Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.94) | Revenue Per Share 0.007 | Quarterly Revenue Growth (1.00) | Return On Assets (0.32) | Return On Equity (0.62) |
The market value of aTyr Pharma is measured differently than its book value, which is the value of ATyr that is recorded on the company's balance sheet. Investors also form their own opinion of ATyr Pharma's value that differs from its market value or its book value, called intrinsic value, which is ATyr Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ATyr Pharma's market value can be influenced by many factors that don't directly affect ATyr Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ATyr Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if ATyr Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ATyr Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.